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Background: We sought to evaluate the effects of aortic annulus size on valve
hemodynamics and clinical outcomes in those patients included in the PARTNER
randomized controlled trial (RCT) cohort A and the PARTNER non-randomized
continued access (NRCA) cohort.
Methods: Patients included the RCT (n¼574) and NRCA (n¼1358) cohorts were
divided in tertiles according to aortic annulus diameter (small, medium, large aortic
annulus; SAA, MAA and LAA, respectively) as measured by transthoracic echocar-
diography. Moderate-to-severe prosthesis-patient mismatch (PPM) was deﬁned as an
effective aortic oriﬁce area of 0.85 cm2/m2.
Results: In the RCT cohort, patients in the SAA tertile who underwent TAVR had a
lower incidence of PPM (39% vs. 63%, P¼0.01), and only a trend toward a higher
incidence of moderate-to-severe paravalvular leak (PVL) compared to SAVR (5.7%
vs. 0%, P¼0.06). In the LAA tertile, there were no differences in the rate of PPM
between groups and a signiﬁcant increase in moderate-to-severe PVL was associated
with TAVR (9% vs. 0%, P¼0.01). In the NRCA cohort, there were no differences in
PPM between the SAA and LAA tertiles, but a higher rate of moderate-to-severe PVL
was observed in the LAA tertile (5.9% vs. 11.5%, P¼0.004). Patients in the LAA
tertile had a higher mortality rate at 1-year follow-up compared to the SAA and MAA
tertiles (24.8%, 18.3% and 18.7%, respectively, P¼0.02), and differences persisted in
multivariable analysis (P¼0.048 for LAA vs. MAA, P¼0.035 for LAA vs. SAA).
Conclusions: Aortic annulus sizehad amajor impact onvalvehemodynamics and clinical
outcomes following AVR. This study highlights the importance of considering aortic
annulus size in the evaluation of high-risk patients who are candidates for AVR, and
suggests that TAVR may be the preferred strategy for those with smaller aortic annulus.
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Background: Transcatheter aortic valve-in-valve (VinV) implantation inside failed
bioprostheses is increasingly being performed. Stentless surgical valves lack ﬂuoro-
scopic markers and may pose unique challenges. We aimed to evaluate clinical out-
comes following aortic VinV procedures in stentless bioprostheses, using a large
global registry.
Methods: Aortic VinV procedures included in the Global Valve-in-Valve Registry
were investigated (553 procedures: 441 in stented bioprostheses, 112 stentless).
Results: Patients with failed stentless bioprostheses were younger and had similar
STS score in comparison with those with stented (73.4  13.9 vs. 78.6  8, p< 0.001;
10.7  8.3 vs. 12.1  10.6, p¼0.20, respectively). Stentless bioprostheses had a
longer median time to failure and failed more commonly with predominant regurgi-
tation (11 vs. 9 years, p¼0.02 and 58.9% vs. 21.8% in stented, p< 0.001), were larger
(23.8  2.1 vs. 23.0  2.1 in stented, p¼0.002) and had lower degree of stenosis in
comparison with stented: valve area 1.28  0.62cm2 vs. 0.88  0.43cm2, mean
gradient 48  28.6 mmHg vs. 64.7  26.8mmHg, respectively; p< 0.001 for both).
Stentless bioprostheses were more commonly treated by a CoreValve (65.1% vs.
34.7% SAPIEN, p< 0.001) and TEE was utilized more during these procedures
(75.2% vs. 62.6% in stented, p¼0.01). Device malposition was more common in
stentless and Mosaic stented valves (16.1%, 14.0% vs. 9.0% in non-Mosaic stented
valves, p¼0.03). Coronary occlusion was more common in stentless bioprostheses
(5.4% vs. 1.4% in stented, respectively, p¼0.01). Post procedural mean aortic valve
gradient was lower post stentless VinV procedures (11.7  7.2mmHg vs. 16.9 
9.1mmHg in stented, p< 0.001). Thirty-day and 1-year mortality rates were similar,
when comparing stented and stentless procedures: 8.9% vs.6.6% (p¼0.39), 17.9% vs.
16.6% (p¼0.68), respectively.
Conclusions: Aortic VinV implantation inside stentless bioprosthesis is challenging
and associated with more device malposition and coronary occlusion events. Never-
theless, VinV procedures performed in stentless bioprostheses resulted better valve
hemodynamics than in stented surgical valves and patient survival was similar.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaTCT-699
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Background: It is important to elucidate factors that are associated with a poor
outcome after transcatheter aortic valve replacement (TAVR) to improve patient se-
lection. Tricuspid regurgitation (TR) and right ventricular dysfunction (RVD)
adversely affect outcomes in patients with heart failure or mitral valve disease, but
their impact on outcomes in patients with severe aortic stenosis (AS) treated with
TAVR has not been well characterized.
Methods: Patients enrolled and treated in the PARTNER II trial (inoperable cohort)
(n¼553) were included and stratiﬁed according to the presence and severity of TR and
RVD (qualitatively measured) on the baseline (pre-TAVR) echocardiogram as
determined by a core lab. Multivariable Cox PH models were used to evaluate the
association between TR and RVD and 1-year all-cause death.
Results: TR severity and RV function were measured in 507 and 488 patients,
respectively. Patients with none/trace (n¼167), mild (n¼205), moderate (n¼117), and
severe (n¼18) TR had 1-year all-cause death rates of 16.9%, 17.2%, 32.6%, and
61.1%, respectively (p< 0.001). Patients with normal RV function (n¼335) and mild
(n¼110) or moderate/severe RVD (n¼39) had 1 year all-cause death rates of 19.0%,
25.5%, and 38.5%, respectively (p< 0.001). Increasing severity of TR (p¼0.003) and
RVD (p¼0.01) were also associated with increased re-hospitalization rates at 1 year.
After adjusting for age, sex, BMI, STS score, prior infarct, prior CABG, frailty,
permanent pacemaker, atrial ﬁbrillation, left ventricular ejection fraction, aortic
transvalvular mean gradient, and mitral regurgitation, moderate/severe TR was asso-
ciated with increased 1-year mortality (adjusted HR 1.73, 95% CI 1.09-2.75, p¼0.01),
whereas RVD was not (p¼0.67).
Conclusions: In very high risk patients with severe symptomatic AS undergoing
TAVR, moderate or severe TR is independently associated with increased 1-year
mortality whereas RVD was only associated with mortality in univariable analysis.
This may have implications for treatment decisions, including assessment of antici-
pated beneﬁt from TAVR and whether concomitant surgical treatment of TR should
be considered in operable patients.
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Background: Data on degree of device oversizing associated with optimal clinical
outcomes after transcatheter aortic valve replacement (TAVR) is limited.
Methods: multicenter analyses of consecutive transfemoral TAVR procedures
using either SAPIEN XT or CoreValve was utilized. Oversizing zones were deﬁned
for SAPIEN XT (5-20% area oversizing or 2.5-9.5% perimeter oversizing) and
for CoreValve (20-35% area oversizing or 9.5-16.2% perimeter oversizing). “favor-
able-SAPIEN XT” (FXT) zone and “favorable-CoreValve” (FCV) zone included
annular sizes for which implantation of either a SAPIEN XT or a CoreValve,
respectively, allowed for presumed favorable oversizing.
Results: A total of 368 patients were included in the study: 178 patients in the FCV
zone (treated by either CoreValve, n¼90 or SAPIEN XT, n¼88) and 190 patients in
the FXT zone (treated by either SAPIEN XT, n¼78, or CoreValve, n¼112). In FCV
zone, those treated by SAPIEN XT had more annular rupture and conversion to
cardiac surgery in comparison with those treated by CoreValve (3.4% vs. 0, p¼0.04
and 4.5% vs. 0, p¼0.02, respectively). In FXT zone, those treated by CoreValve hadlvular disease - Aortic: TAVR B205
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by SAPIEN XT (16.1% vs. 7.7%, p¼0.04 and 8% vs. 1.3%, p¼0.02, respectively).
Conclusions: Optimal clinical performance of CoreValve and SAPIEN XT appears to
be reached with different degrees of device oversizing. An individualized-device-
approach during TAVR, utilizing a speciﬁc device for a speciﬁc annulus size, enabling
favorable degree of oversizing, may improve clinical outcomes. This approach should
be further validated in randomized trials.
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Background: TAVR is an alternative to surgery in high risk operable patients;
however, complications and cost currently limit expansion into lower risk populations.
Although mortality, morbidity and length of stay (LOS) are expected to improve, we
sought to determine if a multidisciplinary, multimodality, but minimalist (3M)
approach could improve outcomes with currently available valve technology.
Methods: Patients considered high risk for surgery, but relatively low risk for TAVR,
were rigorously screened with functional and cognitive assessments as well as multi-
modality imaging. From a potential pool of 335 accepted transfemoral TAVR patients,
73 (22%) were selected for the 3M approach and underwent SAPIEN XT (Edwards
Lifesciences Inc., CA, USA) valve implantation. All procedures in the second half of the
cohort (38/73) were performed awake with no sedation and only femoral monitoring.
Thirty day and one year outcomes were reported according to VARC-2 guidelines.
Results: The mean patient age was 837 years with a mean STS score of 8.33.7%.
All-cause mortality or major stroke at 30 days and 1 year was 1.4% (1/73) and 8% (4/
50) respectively. Procedural events at 30 days included life-threatening bleeding
(1.4%), major vascular complications (2.7%), and need for permanent pacemaker
(2.7%). The median LOS was 1 day (IQR1-2) with a mean LOS of 1.71.5 days. The
mean LOS for the initial intubated cohort (35/73) vs the awake cohort (38/73) was
2.12 vs 1.31 days respectively (p¼0.03). Overall, 50/73 (68%) were discharged
home one day post TAVR with 2 readmissions (2.7%) within 30 days. Aortic valve
area increased from 0.70.14 cm2 to 1.690.29 cm2 (p< 0.001) at 30 days and
1.50.25cm2 (p< 0.001) at 1 year; mean trans-aortic gradient decreased from 4318
mmHg to 9  3 mmHg (p < 0.001) at 30 days and 115 mmHg (p < 0.001) at 1 year.
At 30 days and 1 year, 98% (71/73) and 92% (46/50) were NYHA class I or II with
mild or less paravalvular regurgitation.
Conclusions: Rigorous patient screening as well as improvements in procedural
guidance, device selection, and adherence to the 3M clinical pathway permits safe
next day discharge home in high risk patients with a 92% survival rate at 1 year.
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Background: Aortic Valve-in-Valve (VinV) is limited by device underexpansion and
elevated post procedural gradients. Supraanular position of the transcatheter heart
valve (THV) device in relation to the failed surgical valve is suggested to be
advantageous. No comprehensive analysis of implant depth in valve-in-valve and post
procedural hemodynamics was reported.
Methods: Analyses of cases included in the global VinV registry was performed.
Only cases with implantation of either SAPIEN XT or CoreValve were included in
the analysis. Cases performed inside surgical valves without ﬂuoroscopic markers on
bioprosthesis basal ring (e.g. stentless, homografts, Mosaics), or those with subop-
timal images, were excluded. Implant depth was deﬁned in CoreValve cases in
absolute length and in SAPIEN cases in percentage of the THV device below the
surgical valve ring. Evaluation of implantation depth was performed by an analyst
blinded to clinical outcomes. Elevated post procedural gradients were deﬁned as
mean  20mmHg.
Results: A total of 100 aortic vinv cases were analyzed (60% CoreValve, 40%
SAPIEN). Median implanted depth of of the CoreValve device was 7.7mm (inter-
quartile range, IQR, 5.4-10.1mm) and of the SAPIEN device median of 20.3% of
device length below the ring (IQR 7.9-25.5%). Post implantation echocardiographic
results in the total group included: aortic valve area 1.49  0.47cm2, mean gradient 16
 6.9mmHg. Elevated post procedural gradients were recorded in 27% of patients
(16.7% of CoreValve cases, 42.5% of SAPIEN cases). In CoreValve cases implant
depth was strongly associated with elevated gradients (6mm, 22.7%, < 6mm, 0%,
p¼0.04) but not with the surgical valve size (label21mm 17.2%, >21mm 15.6%,
p¼0.34). In SAPIEN cases, association between elevated gradients and surgical valve
size existed (label21mm 66.7%, >21mm 28%, p¼0.02) but not with implant depth
(20% below the bioprosthesis ring, 45%, < 20% below the bioprosthesis ring, 40%,
p¼0.87).
Conclusions: Elevated post-procedural gradients are common after aortic VinV.
Signiﬁcant contributors for elevated gradients are deep implantation of a CoreValve
device and SAPIEN implantation inside a small surgical valve.
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Background: Stroke occurrence in patients undergoing transcatheter aortic valve
implantation (TAVI) has been reported among complications in several studies. The
aim of this study was to assess the impact of periprocedural stroke on mortality at mid-
term follow-up after TAVI.
Methods: Six-hundred-ﬁfty-six patients with aortic stenosis underwent TAVI with the
CoreValve system (92.8%) or the Edwards SAPIEN valve system (7.2%). Stroke and
transient ischemic attack were deﬁned according to the Valve Academic Research
Consortium-2 consensus document. A cerebrovascular accident (CVA) was deﬁned as
any stroke or transient ischemic attack. Periprocedural events were deﬁned as events
occurring within 72 hours from the index procedure. Multivariable Cox regression
analyses were performed to calculate hazard ratio (HR) with 95% conﬁdence intervals
(CI) of mortality.
Results: Procedural success occurred in 97.4% of patients. The incidence of any
stroke and of CVA after the index procedure was 2.4% and 2.7%, respectively.
Periprocedural strokes accounted for 56.2% of all strokes and occurred in 1.4% of
patients included in the study. Periprocedural CVA accounted for 55.6% of all CVA
and occurred in 1.5% of patients. After a median follow-up of 434 days, all-cause
mortality and cardiac mortality were signiﬁcantly higher in patients with periproce-
dural stroke as compared to those without (66.7% vs 22.9%, logrank p¼0.001; 66.7%
vs 16.8%, logrank p< 0.001, respectively); and among patients with periprocedural
CVA as compared to those without (70.0% vs 22.8%, logrank p < 0.001; 70.0% vs
16.7%, logrank p < 0.001, respectively). Periprocedural stroke and CVA were sig-
niﬁcant independent predictors of all-cause mortality (HR 4.67, 95% CI 1.96-11.1,
p< 0.001; HR 4.66, 95% CI 2.06-10.5, p< 0.001, respectively) and of cardiac mor-
tality (HR 6.47, 95% CI 2.75-15.2, p< 0.001; HR 6.74, 95% CI 3.05-14.9, p< 0.001,
respectively).
Conclusions: More than half of strokes and CVA following TAVI occur within the
periprocedural period. Periprocedural stroke and CVA are independent predictors of
all-cause mortality and cardiac mortality at mid-term follow-up. Strategies for peri-
procedural cerebrovascular events prevention are needed.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
